Barclays
CASC

Barclays’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Barclays’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-883
Closed -$11K – 6975
2015
Q3 		$11K Sell
883
-3,850
-81% -$78.9K ﹤0.01% 5754
2015
Q2 		$85K Buy
4,733
+3,250
+219% +$51.4K ﹤0.01% 4784
2015
Q1 		$9K Buy
1,483
+833
+128% +$8.17K ﹤0.01% 6308
2014
Q4 		$4K Buy
+650
New +$7.05K ﹤0.01% 7034
2014
Q3 		– Sell
-433
Closed -$8K – 7946
2014
Q2 		$8K Sell
433
-217
-33% -$3.83K ﹤0.01% 6967
2014
Q1 		$8K Sell
650
-400
-38% -$6.57K ﹤0.01% 7046
2013
Q4 		$6K Buy
1,050
+383
+57% +$4.28K ﹤0.01% 7155
2013
Q3 		$8K Sell
667
-783
-54% -$8.24K ﹤0.01% 6870
2013
Q2 		$14K Buy
+1,450
New +$18.6K ﹤0.01% 7004

Barclays's CASC Position: Q1 2018 in Review

Barclays sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 6,125 shares — an estimated $23K sold.

Barclays first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $126K in Q2 2013. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Barclays reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Barclays sold 6,125 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $23K.
  • Barclays first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
  • Barclays's Cascadian Therapeutics, Inc. position peaked at $126K in Q2 2013.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.